|
Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
Travel, Accommodations, Expenses - UroToday |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - InVitae |
|
|
|
Stock and Other Ownership Interests - Invitae |
Travel, Accommodations, Expenses - Invitae |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Invitae |
Honoraria - Third Rock Ventures |
Consulting or Advisory Role - Genome Medical; Pfizer |
Patents, Royalties, Other Intellectual Property - I receive roylaties from NIH and the University of California for a mouse model I created |
Travel, Accommodations, Expenses - Pfizer |
|
|
Leadership - Capio BioSciences (I) |
Stock and Other Ownership Interests - Capio Biosciences (I) |
Honoraria - Exelixis; Genentech/Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Pfizer; Pharmacyclics; Sanofi |
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Genzyme |
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst) |
Travel, Accommodations, Expenses - Acerta Pharma |
|
|
Honoraria - Bayer; Exelixis |
Research Funding - Agensys (Inst); Bayer (Inst); Clovis Oncology (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst) |
Travel, Accommodations, Expenses - Clovis Oncology |
|
|
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer; Sanofi |
Speakers' Bureau - Exelixis; Genentech |
Research Funding - Acerta Pharma (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst) |
|
|
Leadership - Capio BioSciences |
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi |
Speakers' Bureau - Bayer; Exelixis; Sanofi |
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi |
|
|
Patents, Royalties, Other Intellectual Property - patent awarded for discovery of HOXB13 as prostate cancer susceptibility gene (Inst) |
|
|
Honoraria - Dendreon; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi |
Speakers' Bureau - Bayer; Dendreon; Sanofi |
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst) |
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech |